Phase 1 oncology trials and informed consent
Ethical concerns have been raised about the quality of informed consent by participants in phase 1 oncology trials. Interview surveys indicate that substantial proportions of trial participants do not understand the purpose of these trials—evaluating toxicity and dosing for subsequent efficacy studi...
| Authors: | ; |
|---|---|
| Format: | Electronic Article |
| Language: | English |
| Check availability: | HBZ Gateway |
| Journals Online & Print: | Drawer...
|
| Fernleihe: | Fernleihe für die Fachinformationsdienste |
| Published: |
BMJ Publ.
2013
|
| In: |
Journal of medical ethics
Year: 2013, Volume: 39, Issue: 12, Pages: 761-764 |
| Online Access: |
Volltext (JSTOR) Volltext (lizenzpflichtig) Volltext (lizenzpflichtig) |
MARC
| LEADER | 00000caa a22000002 4500 | ||
|---|---|---|---|
| 001 | 1816147168 | ||
| 003 | DE-627 | ||
| 005 | 20230426115748.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220908s2013 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1136/medethics-2012-100832 |2 doi | |
| 035 | |a (DE-627)1816147168 | ||
| 035 | |a (DE-599)KXP1816147168 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 1 |2 ssgn | ||
| 100 | 1 | |e VerfasserIn |0 (DE-588)124141986 |0 (DE-627)085665177 |0 (DE-576)165759062 |4 aut |a Miller, Gabriele |d 1923-2010 | |
| 109 | |a Miller, Gabriele 1923-2010 |a Miller, G. 1923-2010 | ||
| 245 | 1 | 0 | |a Phase 1 oncology trials and informed consent |
| 264 | 1 | |c 2013 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Ethical concerns have been raised about the quality of informed consent by participants in phase 1 oncology trials. Interview surveys indicate that substantial proportions of trial participants do not understand the purpose of these trials—evaluating toxicity and dosing for subsequent efficacy studies—and overestimate the prospect of therapeutic benefit that they offer. In this article we argue that although these data suggest the desirability of enhancing the process of information disclosure and assessment of comprehension of the implications of study participation, they do not necessarily invalidate consent by phase 1 trial participants. | ||
| 700 | 1 | |a Joffe, Steven |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of medical ethics |d London : BMJ Publ., 1975 |g 39(2013), 12, Seite 761-764 |h Online-Ressource |w (DE-627)323607802 |w (DE-600)2026397-1 |w (DE-576)260773972 |x 1473-4257 |7 nnns |
| 773 | 1 | 8 | |g volume:39 |g year:2013 |g number:12 |g pages:761-764 |
| 856 | |3 Volltext |u http://www.jstor.org/stable/43282892 |x JSTOR | ||
| 856 | 4 | 0 | |u https://doi.org/10.1136/medethics-2012-100832 |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u http://jme.bmj.com/content/39/12/761.abstract |x Verlag |z lizenzpflichtig |3 Volltext |
| 935 | |a mteo | ||
| 936 | u | w | |d 39 |j 2013 |e 12 |h 761-764 |
| 951 | |a AR | ||
| ELC | |a 1 | ||
| ITA | |a 1 |t 1 | ||
| LOK | |0 000 xxxxxcx a22 zn 4500 | ||
| LOK | |0 001 4185601069 | ||
| LOK | |0 003 DE-627 | ||
| LOK | |0 004 1816147168 | ||
| LOK | |0 005 20220908053617 | ||
| LOK | |0 008 220908||||||||||||||||ger||||||| | ||
| LOK | |0 035 |a (DE-Tue135)IxTheo#2022-08-03#6786B5FAB0EECB9052B1E24163FF6CF36EB21C20 | ||
| LOK | |0 040 |a DE-Tue135 |c DE-627 |d DE-Tue135 | ||
| LOK | |0 092 |o n | ||
| LOK | |0 852 |a DE-Tue135 | ||
| LOK | |0 852 1 |9 00 | ||
| LOK | |0 866 |x JSTOR#http://www.jstor.org/stable/43282892 | ||
| LOK | |0 935 |a ixzs |a ixrk |a zota | ||
| OAS | |a 1 |b inherited from superior work | ||
| ORI | |a SA-MARC-ixtheoa001.raw | ||